BioLife Solutions, Inc. – NASDAQ:BLFS
BioLife Solutions stock price today
$24.52
-2.07
-7.78%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
BioLife Solutions stock price monthly change
+28.33%
month
BioLife Solutions stock price quarterly change
+28.33%
quarter
BioLife Solutions stock price yearly change
+57.71%
year
BioLife Solutions key metrics
Market Cap | 1.23B |
Enterprise value | N/A |
P/E | -5.9 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 5.13 |
Price/Book | 2.28 |
PEG ratio | N/A |
EPS | -1.42 |
Revenue | 137.29M |
EBITDA | -44.51M |
Income | -62.93M |
Revenue Q/Q | -15.85% |
Revenue Y/Y | -15.89% |
Profit margin | -85.79% |
Oper. margin | -89.37% |
Gross margin | 33.27% |
EBIT margin | -89.37% |
EBITDA margin | -32.42% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioLife Solutions stock price history
BioLife Solutions stock forecast
BioLife Solutions financial statements
Average Price Target
$30
Potential upside: 22.34%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 39.50M | -10.19M | -25.82% |
|---|---|---|---|
| Sep 2023 | 33.32M | -29.13M | -87.41% |
| Dec 2023 | 32.73M | -13.38M | -40.89% |
| Mar 2024 | 31.72M | -10.22M | -32.22% |
| Jun 2023 | 433177000 | 81.04M | 18.71% |
|---|---|---|---|
| Sep 2023 | 411152000 | 79.13M | 19.25% |
| Dec 2023 | 412714000 | 75.05M | 18.18% |
| Mar 2024 | 401602000 | 68.19M | 16.98% |
| Jun 2023 | -7.71M | 9.29M | 704K |
|---|---|---|---|
| Sep 2023 | -4.37M | 1.66M | 608K |
| Dec 2023 | 2.31M | 3.95M | 9.84M |
| Mar 2024 | -4.47M | -221K | -952K |
BioLife Solutions alternative data
| Aug 2023 | 466 |
|---|---|
| Sep 2023 | 466 |
| Oct 2023 | 466 |
| Nov 2023 | 466 |
| Dec 2023 | 466 |
| Jan 2024 | 466 |
| Feb 2024 | 466 |
| Mar 2024 | 409 |
| Apr 2024 | 409 |
| May 2024 | 409 |
| Jun 2024 | 409 |
| Jul 2024 | 409 |
BioLife Solutions other data
81.14%
+0.27%
of BLFS is owned by hedge funds
157
-10
35.13M
+118.84K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 13704 |
| Feb 2024 | 0 | 585 |
| Mar 2024 | 0 | 56215 |
| Apr 2024 | 0 | 17111 |
| May 2024 | 0 | 12617 |
| Jun 2024 | 0 | 10000 |
| Jul 2024 | 0 | 5155 |
| Aug 2024 | 0 | 495 |
| Sep 2024 | 0 | 24887 |
| Oct 2024 | 0 | 22232 |
| Nov 2024 | 0 | 44952 |
| Dec 2024 | 0 | 20800 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MATHEW ABY J. officer: EVP & Ch.. | Common Stock | 13,196 | $27.16 | $358,403 | ||
Sale | MATHEW ABY J. officer: EVP & Ch.. | Common Stock | 7,604 | $27.33 | $207,817 | ||
Sale | WICHTERMAN TROY officer: Chief Financial Officer | Common Stock | 581 | $27.2 | $15,803 | ||
Sale | MATHEW ABY J. officer: EVP & Ch.. | Common Stock | 523 | $27.2 | $14,226 | ||
Sale | BERARD TODD officer: Chief Ma.. | Common Stock | 349 | $27.2 | $9,493 | ||
Sale | AEBERSOLD SARAH officer: Chief Human Resources .. | Common Stock | 216 | $27.2 | $5,875 | ||
Sale | FOSTER KAREN A. officer: Chief Qu.. | Common Stock | 252 | $27.2 | $6,854 | ||
Sale | MATHEW ABY J. officer: EVP & Ch.. | Common Stock | 17,604 | $20.05 | $352,960 | ||
Option | MATHEW ABY J. officer: EVP & Ch.. | Common Stock | 10,000 | $2.06 | $20,600 | ||
Sale | MATHEW ABY J. officer: EVP & Ch.. | Common Stock | 10,000 | $21.16 | $211,600 |
| Patent |
|---|
Application Filling date: 2 Oct 2019 Issue date: 27 Jan 2022 |
Application Filling date: 8 Apr 2020 Issue date: 14 Oct 2021 |
Application Filling date: 8 Apr 2020 Issue date: 14 Oct 2021 |
Application Filling date: 5 Jan 2021 Issue date: 22 Jul 2021 |
Application Filling date: 11 Apr 2019 Issue date: 13 May 2021 |
Grant Filling date: 23 May 2017 Issue date: 9 Feb 2021 |
Grant Filling date: 16 Jan 2018 Issue date: 4 Aug 2020 |
Grant Filling date: 14 May 2015 Issue date: 4 Feb 2020 |
Grant Utility: Cryogenic workstation using nitrogen Filling date: 3 Jun 2014 Issue date: 14 Jan 2020 |
Application Filling date: 31 May 2019 Issue date: 5 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2024 29 Feb 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry
BioLife Solutions: A Complicated Tale
BioLife Hit By An Inventory Correction
BioLife Solutions: Capitalizing On The Future Of Biopreservation
BioLife Solutions Is Set To Finally Absorb Its Acquisitions
BioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain Hold
Cryoport: The Golden Stock
BioLife: What The Future Holds
Cryoport: A Rare Investing Opportunity
-
What's the price of BioLife Solutions stock today?
One share of BioLife Solutions stock can currently be purchased for approximately $24.52.
-
When is BioLife Solutions's next earnings date?
Unfortunately, BioLife Solutions's (BLFS) next earnings date is currently unknown.
-
Does BioLife Solutions pay dividends?
No, BioLife Solutions does not pay dividends.
-
How much money does BioLife Solutions make?
BioLife Solutions has a market capitalization of 1.23B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.43% to 143.27M US dollars.
-
What is BioLife Solutions's stock symbol?
BioLife Solutions, Inc. is traded on the NASDAQ under the ticker symbol "BLFS".
-
What is BioLife Solutions's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of BioLife Solutions?
Shares of BioLife Solutions can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioLife Solutions's key executives?
BioLife Solutions's management team includes the following people:
- Mr. Michael P. Rice Chairman & Chief Executive Officer(age: 62, pay: $514,710)
- Dr. Aby J. Mathew Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer(age: 53, pay: $407,640)
- Mr. Roderick de Greef Pres & Chief Operating Officer(age: 65, pay: $390,890)
- Ms. Karen Foster Chief Quality Officer(age: 65, pay: $345,730)
- Mr. Todd Berard Chief Marketing Officer(age: 56, pay: $286,490)
-
How many employees does BioLife Solutions have?
As Jul 2024, BioLife Solutions employs 409 workers.
-
When BioLife Solutions went public?
BioLife Solutions, Inc. is publicly traded company for more then 35 years since IPO on 22 Nov 1989.
-
What is BioLife Solutions's official website?
The official website for BioLife Solutions is biolifesolutions.com.
-
Where are BioLife Solutions's headquarters?
BioLife Solutions is headquartered at 3303 Monte Villa Parkway, Bothell, WA.
-
How can i contact BioLife Solutions?
BioLife Solutions's mailing address is 3303 Monte Villa Parkway, Bothell, WA and company can be reached via phone at 425 402 1400.
-
What is BioLife Solutions stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for BioLife Solutions in the last 12 months, the avarage price target is $30. The average price target represents a 22.34% change from the last price of $24.52.
BioLife Solutions company profile:
BioLife Solutions, Inc.
biolifesolutions.comExchange:
NASDAQ
Full time employees:
409
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
3303 Monte Villa Parkway
Bothell, WA 98021
Bothell, WA 98021
CIK: 0000834365
ISIN: US09062W2044
CUSIP: 09062W204
